TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Phase 1

Completed

• Conditions: Ovarian Neoplasms

• Registration Number: NCT00052065
• Lead Sponsor: Telik

Brief Summary

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-01-21
• Study First Submitted QC: 2003-01-22
• Study First Posted: 2003-01-23
• Study Start: 2003-02
• Primary Completion: 2006-03
• Study Completion: 2006-03
• Status Verified: 2011-06
• Last Update Submitted: 2011-07-21
• Last Update Posted: 2011-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

M.D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States